Gennady Bratslavsky, MD
Urology · Syracuse, NYNPI 1508093121
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,388 of the $15,448 with a category attached, or 73.7%. 7 manufacturers reported payments, led by NS Pharma, Inc. at 47.3% of the total. Reporting peaked in 2021 at $8,665 and has fallen 99.2% since, to $70 in 2025.
Across 22 payments — averaging $702.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- NS Pharma, Inc.$7K
- Merck$5K
- Janssen Research & Development, LLC$3K
- Pfizer$348
- Astellas Pharma US Inc$140
- QED Therapeutics, Inc.$135
- plus $70 from 1 others
Across 139 payments — averaging $18,232 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$1.8M
- Progenics Pharmaceuticals, Inc.$414K
- Genentech, Inc.$231K
- Astellas Pharma Global Development$70K
- Sumitomo Pharma America, Inc.$28K
- Pfizer$23K
- plus $12K from 2 others
What the payments were for
- Consulting fees$11,38874%
- Speaking & faculty fees$3,20021%
- Food & beverage$8425%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| NS Pharma, Inc. | 8 | $7,300 |
| Merck | 3 | $4,781 |
| Janssen Research & Development, LLC | 5 | $2,675 |
| Pfizer | 3 | $348 |
| Astellas Pharma US Inc | 1 | $140 |
| QED Therapeutics, Inc. | 1 | $135 |
| Irras USA, Inc. | 1 | $70 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,448 in reported general payments places this provider in the 85th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 13 | $9,326 |
| MyrbetriqMirabegron | 12 | $8,686 |
| Tamsulosin Hcl | 117 | $1,607 |
| Solifenacin Succinate | 19 | $1,598 |
| Trospium Chloride | 20 | $1,197 |
| Finasteride | 50 | $649 |
| Dutasteride | 23 | $447 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 28 | $321 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 15 | $203 |
| Oxybutynin Chloride ErOxybutynin Chloride | 23 | $197 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $24 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $140 | $8,68612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 952 urology providers in New York.
Other urology in Syracuse
- Christopher PieczonkaSyracuse$797K
- David AlbalaSyracuse$139K
- Andrew StephensonSyracuse$95K
- Po LamSyracuse$81K
- Peter WalterJamestown$1.9M
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Jeffrey SpencerCheektowaga$430K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.